Advertisement
Advertisement

PRE

PRE logo

Prenetics Global Limited - Class A

5.69
USD
-0.14
-2.40%
Dec 31, 13:01 UTC -5
Closed
...

Prenetics Global Limited - Class A Profile

About

Prenetics, a leading genomics-driven health sciences company, is revolutionizing prevention, early detection, and treatment. Their prevention arm, CircleDNA, uses whole exome sequencing to offer the world's most comprehensive consumer DNA test. Insighta, their joint venture with renowned scientist Prof. Dennis Lo, underscores their unwavering commitment to saving lives through pioneering multi-cancer early detection technologies. Lastly, ACT Genomics, their treatment unit, is the first Asia-based company to achieve FDA clearance for comprehensive genomic profiling of solid tumors via ACTOnco. Each of Prenetics' units synergistically enhances their global impact on health, truly embodying their commitment to 'enhancing life through science'.

Info & Links

CEO

Yeung Danny Sheng Wu

Headquarters

Unit 703-706, K11 Atelier King¿s Road, 728 King¿s Road
Quarry Bay, K3 , HONG KONG

Sector

Finance

Website

--

Auditor

KPMG

Share holders

--

Employees

320

Prenetics Global Limited - Class A Statistics

Valuation Measures

Market Capitalization2

39.29M

Enterprise Value

7.35M

Enterprise Value/EBITDA(ttm)

-0.18

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

2.08

Price to Book(mrq)

0.30

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

55.59%

Operating Margin(ttm)

-126.17%

Profit Margin(ttm)

-190.87%

Return on Equity(ttm)

-16.45%

Return on Invested Capital(ttm)

-22.87%

Return on Assets(ttm)

-13.34%

Income Statement

Revenue(ttm)

25.56M

Revenue Per Share(ttm)

--

Gross Profit(ttm)

14.17M

EBITDA(ttm)3

-40.80M

Net Income Available to Common(ttm)

-46.91M

Diluted EPS(ttm)

-3.99

Share Statistics

Beta (5Y Monthly)

-0.18

52-Week Change

33.26%

S&P 500 52-Week Change

23.74%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

--

Dividend Yield

0.00%

Float4

0.00

% Held by Insiders

--

% Held by Institutions

25.01%

Balance Sheet

Total Cash(mrq)

31.94M

Total Cash Per Share(mrq)

--

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

1.40%

Quick Ratio(mrq)

1.22%

Book Value Per Share(mrq)

--

Cash Flow

Operating Cash Flow Per Share(ytd)

--

Free Cash Flow(ytd)

0.00

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement